43 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp00704 | 10a | NA | Synthetic b2,2-amino acid derivatives | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 28 µM |
| dbacp00705 | 10b | NA | Synthetic b2,2-amino acid derivatives | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 11.4 µM |
| dbacp00706 | 10c | NA | Synthetic b2,2-amino acid derivatives | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 6.6 µM |
| dbacp00707 | 11a | NA | Synthetic b2,2-amino acid derivatives | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 5.2 µM |
| dbacp00708 | 11b | NA | Synthetic b2,2-amino acid derivatives | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 19 µM |
| dbacp00709 | 11c | NA | Synthetic b2,2-amino acid derivatives | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 7.2 µM |
| dbacp00710 | 12a | NA | Synthetic b2,2-amino acid derivatives | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 6.1 µM |
| dbacp00711 | 12b | NA | Synthetic b2,2-amino acid derivatives | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 27 µM |
| dbacp00712 | 12c | NA | Synthetic b2,2-amino acid derivatives | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 14 µM |
| dbacp00722 | 5a | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 10.6 µM |
| dbacp00723 | 5b | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 7.1 µM |
| dbacp00724 | 5c | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 4.1 µM |
| dbacp00727 | 6a | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 14.4 µM |
| dbacp00728 | 6b | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 11.0 µM |
| dbacp00729 | 6c | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 4.3 µM |
| dbacp00730 | 7a | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : >63 µM |
| dbacp00731 | 7b | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : >78 µM |
| dbacp00732 | 7c | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 79 µM |
| dbacp00733 | 8a | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 136 µM |
| dbacp00734 | 8b | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : >254 µM |
| dbacp00735 | 8c | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 107 µM |
| dbacp00736 | 9a | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 31 µM |
| dbacp00737 | 9b | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 2.3 µM |
| dbacp00738 | 9c | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 3.1 µM |
| dbacp01440 | BAA-1 | NA | Bovine lactoferrin (Lf-B) | Destabilizing the cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 8.1 µg/ml |
| dbacp01441 | BAA-2 | NA | Bovine lactoferrin (Lf-B) | Apoptosis inducing | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 3.8 µg/ml |
| dbacp02145 | C1 | KKWβ2,2WKK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 10 ±2 µMol/L |
| dbacp02146 | C1 | KKWβ2,2WKK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 22 ±5 µMol/L |
| dbacp02148 | C2 | KWβ2,2WKK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 7.9 ± 0.3 µMol/L |
| dbacp02149 | C2 | KWβ2,2WKK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 1.71 ± 0.6 µMol/L |
| dbacp02150 | C3 | KKβ2,2WKK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 15 ± 2 µMol/L |
| dbacp02151 | C3 | KKβ2,2WKK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 92 ± 2 µMol/L |
| dbacp02152 | C4 | KWβ2,2KK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 12.6 ± 0.6 µMol/L |
| dbacp02153 | C4 | KWβ2,2KK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 99 ± 15 µMol/L |
| dbacp02154 | C5 | KKWβ2,2WKK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 11 ± 2 µMol/L |
| dbacp02155 | C5 | KKWβ2,2WKK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 23 ± 3 µMol/L |
| dbacp02156 | C6 | KWβ2,2WKK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 8 ± 1 µMol/L |
| dbacp02157 | C6 | KWβ2,2WKK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 26 ± 2 µMol/L |
| dbacp02158 | C7 | KKβ2,2WKK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 16 ± 5 µMol/L |
| dbacp02159 | C7 | KKβ2,2WKK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 157 ± 30 µMol/L |
| dbacp02223 | C8 | KWβ2,2KK | Not found | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 20 ± 2 µMol/L |
| dbacp02224 | C8 | KWβ2,2KK | Not found | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 226 ± 21 µMol/L |
| dbacp03740 | LfcinB | FKCRRWQWRMKK | Bovine lactoferrin (Lf-B) | Cell membrane disintegration; Regulation of immune response; Apoptosis | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 10 µM |